Free shipping on all orders over $ 500

VLX1570

Cat. No. M10753
VLX1570 Structure
Synonym:

CS-2226

Size Price Availability Quantity
5mg USD 320  USD320 In stock
10mg USD 500  USD500 In stock
25mg USD 1000  USD1000 In stock
50mg USD 1500  USD1500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

VLX1570 is a competitive inhibitor of proteasome deuteronase (DUBs), with IC50 of 10 μM. VLX1570 (250 nM) downregulates BCR-signalosome components and their end effectors, as well as CXCR4 expression in WM cells. VLX1570 inhibits USP14 and UCHL5 activity of 19S regulatory particles, and the inhibition of USP14 is more pronounced. VLX1570 (1 μM) shows inhibitory activity against USP14 in KMS-11 myeloma cells.

Chemical Information
Molecular Weight 469.39
Formula C23H17F2N3O6
CAS Number 1431280-51-1
Solubility (25°C) DMSO ≥ 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Juan Wang, et al. J Cell Mol Med. VLX1570 regulates the proliferation and apoptosis of human lung cancer cells through modulating ER stress and the AKT pathway

[2] Karthik Selvaraju, et al. Biomolecules. Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System

[3] Nami Kurozumi, et al. Cancer Sci. VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines

[4] Paola Pellegrini, et al. Int J Mol Sci. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570

[5] Eric K Rowinsky, et al. Invest New Drugs. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Related Deubiquitinase Products
TNG348

TNG348 is a novel, oral, potent and selective ubiquitin-specific protease 1 (USP1) inhibitor for studies related to BRCA1/2 mutations and other homologous recombination defect (HRD)+ cancers.

FT-3171

FT-3171 is a small molecule ubiquitin-specific protease 1 (USP1) inhibitor targeting a novel DNA damage repair (DDR) pathway for studies related to solid tumors.

BAY-728

BAY-728 serves as a negative control for BAY-805, a potent and selective USP21 inhibitor.

BAY-805

BAY-805 is a selective inhibitor of the ubiquitin-specific protease USP21 with high selectivity for deubiquitinating enzyme (DUB) targets, kinases, proteases and other common off-target enzymes.

USP1-IN-6

USP1-IN-6 is a USP1 inhibitor (IC50<50 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: VLX1570, CS-2226 supplier, Deubiquitinase, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.